| Variable | N | 40 and below N = 511 |
above 40 N = 5531 |
|---|---|---|---|
| Age | 604 | 32 (26, 35) | 67 (59, 74) |
| Sex | 604 | ||
| Female | 16 (31%) | 217 (39%) | |
| Male | 35 (69%) | 336 (61%) | |
| Race | 604 | ||
| Asian | 4 (7.8%) | 40 (7.2%) | |
| Black or African American | 2 (3.9%) | 20 (3.6%) | |
| Native Hawaiian or Other Pacific Islander | 1 (2.0%) | 0 (0%) | |
| Not reported | 18 (35%) | 151 (27%) | |
| Other | 3 (5.9%) | 12 (2.2%) | |
| Unknown | 0 (0%) | 3 (0.5%) | |
| White | 23 (45%) | 327 (59%) | |
| Ethnicity | 604 | ||
| Hispanic or Latino | 4 (7.8%) | 28 (5.1%) | |
| Not applicable (not a resident of the USA) | 18 (35%) | 142 (26%) | |
| Not Hispanic or Latino | 29 (57%) | 360 (65%) | |
| Unknown | 0 (0%) | 23 (4.2%) | |
| KPS | 594 | ||
| < 90 | 20 (39%) | 329 (61%) | |
| >= 90 | 31 (61%) | 214 (39%) | |
| Unknown | 0 | 10 | |
| LBCL Subtype | 604 | ||
| DLBCL NOS | 25 (49%) | 453 (82%) | |
| High-grade B-cell Ly. | 4 (7.8%) | 77 (14%) | |
| Other LBCL | 22 (43%) | 23 (4.2%) | |
| Stage | 600 | ||
| <=II | 17 (34%) | 163 (30%) | |
| III-IV | 33 (66%) | 387 (70%) | |
| Unknown | 1 | 3 | |
| CAR-T Product | 604 | ||
| Axicabtagene ciloleuce | 37 (73%) | 259 (47%) | |
| Lisocabtagene maraleucel | 11 (22%) | 177 (32%) | |
| Tisagenlecleucel | 3 (5.9%) | 117 (21%) | |
| Bridging Therapy | 600 | 38 (76%) | 432 (79%) |
| Unknown | 1 | 3 | |
| Lines of Therapy | 592 | 2 (2, 3) | 2 (2, 3) |
| Unknown | 2 | 10 | |
| Time from Dx to CAR-T (months) | 600 | 11 (8, 16) | 14 (8, 28) |
| Unknown | 0 | 4 | |
| Primary refractory disease | 600 | 38 (76%) | 218 (40%) |
| Unknown | 1 | 3 | |
| Disease Status pre CAR-T | 598 | ||
| CR | 3 (6.0%) | 65 (12%) | |
| Other | 0 (0%) | 1 (0.2%) | |
| POD | 25 (50%) | 248 (45%) | |
| PR | 15 (30%) | 177 (32%) | |
| SD | 5 (10%) | 43 (7.8%) | |
| Unevaluable | 2 (4.0%) | 14 (2.6%) | |
| Unknown | 1 | 5 | |
| 1 Median (IQR) or Frequency (%) | |||